Clarus Therapeutics Announces Issuance of Patent Covering JATENZO® (testosterone undecanoate)
18 mai 2022 09h05 HE
|
Clarus Therapeutics Holdings, Inc.
JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions Clarus plans to list this patent...
Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering JATENZO® (testosterone undecanoate)
28 avr. 2022 09h05 HE
|
Clarus Therapeutics Holdings, Inc.
JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions Upon issuance, this patent will be...
Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at the Androgen Society 4th Annual Meeting
19 avr. 2022 09h05 HE
|
Clarus Therapeutics Holdings, Inc.
JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions NORTHBROOK, Ill., April 19, 2022 ...
Clarus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
30 mars 2022 16h05 HE
|
Clarus Therapeutics Holdings, Inc.
2021 net revenue increased 119% year-over-year to $14.0 million Fourth quarter 2021 net revenue increased 88% year-over-year to $4.6 million Fourth quarter 2021 total prescription growth for...
Clarus Therapeutics to Report Fourth Quarter and Full Year 2021 Financial and Operating Results
29 mars 2022 16h05 HE
|
Clarus Therapeutics Holdings, Inc.
NORTHBROOK, Ill., March 29, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by...
Clarus Announces Strategic Partnerships for JATENZO® (testosterone undecanoate) with Vault Health and AssistRx – Leaders in Providing Healthcare Services to Patients
24 févr. 2022 08h00 HE
|
Clarus Therapeutics Holdings, Inc.
JATENZO is the first and only FDA-approved oral softgel capsule for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions New offerings...
Clarus Therapeutics Announces Closing of Approximately $15 Million Private Placement
07 déc. 2021 16h05 HE
|
Clarus Therapeutics Holdings, Inc.
Proceeds to support the ongoing commercialization of JATENZO® (testosterone undecanoate) NORTHBROOK, Ill., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus)...
Clarus Therapeutics Announces Issuance of Two New Patents for JATENZO® (testosterone undecanoate)
30 nov. 2021 09h05 HE
|
Clarus Therapeutics Holdings, Inc.
JATENZO is the first and only FDA-approved oral softgel for testosterone replacement therapy (TRT) in adult males who have deficient testosterone due to certain medical conditions Clarus plans to...
Clarus Therapeutics Reports Third Quarter 2021 Financial and Operating Results
18 nov. 2021 16h05 HE
|
Clarus Therapeutics Holdings, Inc.
Third quarter 2021 revenue increased 93% year-over-year to $4.3 million Third quarter 2021 total prescription growth for JATENZO® increased 12% sequentially and 132% year-over-year Conference call...
Clarus Therapeutics to Report Third Quarter 2021 Financial and Operating Results
17 nov. 2021 16h05 HE
|
Clarus Therapeutics Holdings, Inc.
NORTHBROOK, Ill., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by...